Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).

NCT04730544 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT04730544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04730544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 21, 2021
Completion date
April 30, 2028
Enrollment
96 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic, msi-h colorectal cancer